Carisma Therapeutics (NASDAQ:CARM – Get Free Report) is expected to be announcing its resultson Thursday, November 5th. Analysts expect Carisma Therapeutics to post earnings of ($0.1237) per share and revenue of $4.66 million for the quarter.
Carisma Therapeutics Trading Up 100.0%
Shares of CARM stock opened at $0.00 on Wednesday. Carisma Therapeutics has a fifty-two week low of $0.00 and a fifty-two week high of $0.10. The stock has a market capitalization of $16,738.00, a price-to-earnings ratio of 0.00 and a beta of -9.60.
Carisma Therapeutics Company Profile
Carisma Therapeutics, Inc is a clinical-stage biotechnology company focused on developing therapies that harness and genetically engineer myeloid cells, including monocytes and macrophages, to treat cancer and other serious diseases. The company’s platform is designed to create engineered immune cells that can recognize disease-associated targets, enter solid tumors and alter the tumor microenvironment.
Carisma’s primary product candidate is CT-0525, an investigational HER2-targeted chimeric antigen receptor (CAR) monocyte therapy being developed for patients with advanced solid tumors.
Featured Stories
- Five stocks we like better than Carisma Therapeutics
- Marriott’s Earnings Beat Shows Why It’s More Than a Bet on Travel Demand
- Franklin Templeton’s New ETFs Turn Stock Dividends Into Bitcoin—What’s the Catch?
- Apple’s Earnings Beat Comes With a Catch for Investors Heading Into the Holidays
- Palantir’s $2.3 Billion Quarter Puts Its Premium Valuation to the Test
Receive News & Ratings for Carisma Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Carisma Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
